Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates efficient tumor targeting using light-activated terbium-161 onartuzumab in gastric cancer models, indicating a viable platform for targeted radiotheranostics.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cieslik et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: